Anima Biotech's machine learning programme 'reveals new mRNA drug targets'

Anima Biotech is using machine learning to explore the role of mRNA in disease, identifying new therapies. Their mRNA Lighting platform screens for molecules targeting disease pathways, with promising results in IPF. Collaborations with AbbVie and Takeda are advancing drug development.